In the majority of cases, asthma and chronic obstructive pulmonary disease (COPD) are two clearly distinct disease entities. However, in some patients there may be significant overlap between the two conditions. This constitutes an important area of concern because these patients are generally excluded from randomised controlled trials (mostly because of smoking history in the case of asthma or...

interactions. This list was created by exploring the basic biomedical research literature (272 studies: candidate gene and genome-wide association studies) for " repurposed " or " effect modification " randomised trials—that is, studies that genotyped stored samples of participants in placebo controlled trials of cardiovascular drugs and thus enabled a test of the interaction between genotype a...

The ability to utilise a patient’s own genetic expression information to detect the onset of disease, monitor its progression and even suggest possible treatment modalities which have the highest probability of success would undoubtedly provide a mechanism in which to enhance the quality of care and treatment for companion animals. As with all clinical situations, veterinarian decision making i...

Response rates to available treatments for psychological and chronic pain disorders are poor, and there is a considerable burden of suffering and disability for patients, who often cycle through several rounds of ineffective treatment. As individuals presenting to the clinic with symptoms of these disorders are likely to be heterogeneous, there is considerable interest in the possibility that d...

The practice of "evidence-based medicine" aims at the conscientious, explicit and judicious use of the current best evidence in making decisions about the individualised patient care. The clinical genetics evolved from translational genetics research and contributes to the clinical care of patients and families through evidence-based health care in managing inherited disorders through accurate ...

Our understanding of chronic obstructive pulmonary disease (COPD) has changed dramatically over the past two decades. We have moved from an airflow limitation-centric view to the realisation that COPD is a complex and heterogeneous disease, which leads inevitably to the need for personalising the assessment and treatment of patients with COPD. This review provides a brief perspective of the ext...

Various sources of variation in observed response in clinical trials and clinical practice are considered, and ways in which the corresponding components of variation might be estimated are discussed. Although the issues have been generally well-covered in the statistical literature, they seem to be poorly understood in the medical literature and even the statistical literature occasionally sho...

Integration of omics with clinical data through machine learning is the future personalised and precision medicine in systemic sclerosis-associated pulmonary arterial hypertensionhttps://bit.ly/3jsyBoV

Response rates to available treatments for psychological and chronic pain disorders are poor, and there is a considerable burden of suffering and disability for patients, who often cycle through several rounds of ineffective treatment. As individuals presenting to the clinic with symptoms of these disorders are likely to be heterogeneous, there is considerable interest in the possibility that d...